NCT06102902

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2024-06-05Est. Completion: 2027-01-30

Enrollment target: 30 participants

Locations

UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
Los Angeles General Medical Center, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
University of Kansas Clinical Research Center, Fairway, Kansas, United States
University of Kansas Cancer Center, Kansas City, Kansas, United States
University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
UT MD Anderson Cancer Center, Houston, Texas, United States

Colorectal NeoplasmsNeoplasmsIntrahepatic CholangiocarcinomaAdrenocortical CarcinomaMetastasis, Neoplasm

Background: Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors …

Bethesda, United StatesEst. completion Dec 31, 2029

Selected Advanced Solid TumorsColorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.